Alkermes Announces Trial to Evaluate Nemvaleukin in Combination with Pembrolizumab
ARTISTRY-7 will analyze the anti-tumor activity and safety of the combination compared with chemotherapy for individuals with platinum-resistant ovarian cancer.
Alkermes announced the initiation of ARTISTRY-7 to evaluate the anti-tumor activity and safety of intravenously administered nemvaleukin alfa (nemvaleukin) in combination with pembrolizumab compared with chemotherapy for individuals with platinum-resistant ovarian cancer, the company said in a statement.
“ARTISTRY-7 is designed to build upon the durable and deepening responses observed in heavily pre-treated patients with platinum-resistant ovarian cancer in the ongoing ARTISTRY-1 study. We look forward to sharing updates from ARTISTRY-7 as the study progresses and as we advance toward potential registration,” Craig Hopkinson, MD, chief medical officer and executive vice president of research and development at Alkermes, said in the statement.
Nemvaleukin is an immune-oncology candidate that is an investigational engineered interleukin-2 variant immunotherapy.
Alkermes is working with Merck, which developed pembrolizumab and is providing the drug for the study.
ARTISTRY-7 is a global open-label, phase 3, randomized study.
The FDA recently granted Fast Track Designation for the drug combination for the treatment of platinum resistant ovarian cancer.
Alkermes initiates ARTISTRY-7 phase 3 trial of nemvaleukin alfa in patients with platinum-resistant ovarian cancer. Alkermes. News release. October 26, 2021. Accessed on October 26, 2021. https://investor.alkermes.com/news-releases/news-release-details/alkermes-initiates-artistry-7-phase-3-trial-nemvaleukin-alfa